Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis

Next Previous
X
Search
Trial Profile

A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CNM Au8 (Primary)
  • Indications Demyelinating disorders; Multiple sclerosis; Optic nerve disorders
  • Focus Proof of concept; Therapeutic Use
  • Acronyms VISIONARY-MS
  • Sponsors Clene Nanomedicine

    • Most Recent Events

    • 16 Apr 2024 According to a Clene Nanomedicine Media Release, results from VISIONARY-MS Open-label extension study presented at the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver.
    • 16 Apr 2024 Results published in a Clene Nanomedicine Media Release
    • 02 Mar 2024 Results (n=55) assessing long-term safety, efficacy, tolerability, and pharmacokinetics of CNM-Au8 30 mg in patients with stable RMS presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top